Author Correction to: Investigational New Drugs
https://doi.org/10.1007/s10637-021-01068-8
The corresponding author noticed an error on page 4 of the original publication where they state, “Subsequently, in 2020, FDA approved a combination of cetuximab (anti-EGFR monoclonal antibody) and binimetinib for the treatment of patients with adult metastatic colorectal cancer (CRC) harboring a BRAFV600E mutation.”
It is encorafenib instead of binimetinib.
Footnotes
The online version of the original article can be found at 10.1007/s10637-021-01068-8
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.